Evolus (NASDAQ:EOLS) Shares Down 6.2% – Here’s Why

Evolus, Inc. (NASDAQ:EOLS)’s stock price was down 6.2% during trading on Thursday . The stock traded as low as $16.37 and last traded at $16.37. Approximately 203,467 shares traded hands during trading, a decline of 65% from the average daily volume of 585,329 shares. The stock had previously closed at $17.45.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, October 3rd. Barclays raised their price target on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th.

Evolus Stock Down 4.7 %

The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The firm’s fifty day moving average price is $15.65 and its 200-day moving average price is $13.41. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -15.97 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last posted its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. Sell-side analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds have recently modified their holdings of EOLS. Quest Partners LLC acquired a new position in Evolus during the second quarter valued at approximately $43,000. Quarry LP acquired a new stake in shares of Evolus in the 2nd quarter valued at approximately $54,000. Profund Advisors LLC bought a new position in shares of Evolus in the second quarter valued at $130,000. Arizona State Retirement System increased its holdings in Evolus by 9.4% during the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after buying an additional 1,253 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Evolus by 9.9% during the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after acquiring an additional 1,035 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.